Time on boards
- Boards served
- 1
- Current seats
- 1
- Board service
- 4 years
- Director since
- 2023
4 years of board service in total across 1 board, counting each seat separately. Longest: Perspective Therapeutics Inc., 3 years.
Perspective Therapeutics Inc.
Director
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Nov 25, 2024 | Perspective Therapeutics Inc. | Open-market purchase | +3,647 | $3.62 | $13,202 |
| Nov 25, 2024 | Perspective Therapeutics Inc. | Open-market purchase | +2,619 | $3.67 | $9,612 |
| May 31, 2024 | Perspective Therapeutics Inc. | Open-market purchase | +55,000 | $1.38 | $75,900 |
| May 29, 2024 | Perspective Therapeutics Inc. | Open-market purchase | +11,375 | $1.32 | $15,015 |
| May 29, 2024 | Perspective Therapeutics Inc. | Open-market purchase | +18,656 | $1.34 | $24,999 |
| Jan 30, 2024 | Perspective Therapeutics Inc. | Open-market purchase | +18,579 | $0.71 | $13,191 |
| Jan 30, 2024 | Perspective Therapeutics Inc. | Open-market purchase | +5,127 | $0.71 | $3,640 |
| Jan 30, 2024 | Perspective Therapeutics Inc. | Open-market purchase | +57,121 | $0.71 | $40,556 |
| Jan 30, 2024 | Perspective Therapeutics Inc. | Open-market purchase | +42,879 | $0.72 | $30,873 |
| Jan 30, 2024 | Perspective Therapeutics Inc. | Open-market purchase | +3,500 | $0.70 | $2,450 |
| Jan 29, 2024 | Perspective Therapeutics Inc. | Open-market purchase | +4,031 | $0.64 | $2,580 |
| Jan 29, 2024 | Perspective Therapeutics Inc. | Open-market purchase | +21,235 | $0.64 | $13,590 |
| Jan 26, 2024 | Perspective Therapeutics Inc. | Open-market purchase | +12,250 | $0.61 | $7,473 |
| Jan 26, 2024 | Perspective Therapeutics Inc. | Open-market purchase | +14,850 | $0.61 | $9,059 |
| Jan 26, 2024 | Perspective Therapeutics Inc. | Open-market purchase | +8,513 | $0.59 | $5,023 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.